Sign In
Buy IMCR
$29.20
-0.150 (-0.511%)
At Close: Jun 23, 2026
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
10:36am, Wednesday, 07'th May 2025
The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Immunocore reports first quarter financial results and provides a business update
07:00am, Wednesday, 07'th May 2025
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Ph
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
11:00am, Wednesday, 30'th Apr 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the po
Immunocore to present at upcoming investor conferences
08:00am, Wednesday, 02'nd Apr 2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Insiders Make Huge Purchases of These 4 Biotech Stocks
08:40am, Wednesday, 26'th Mar 2025
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
11:25am, Friday, 21'st Mar 2025
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
03:00pm, Monday, 10'th Mar 2025
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Immunocore to present at upcoming investor conferences
07:00am, Monday, 03'rd Mar 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology co
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
08:11am, Thursday, 27'th Feb 2025
Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 milli
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
01:24pm, Wednesday, 26'th Feb 2025
Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Co
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
07:00am, Wednesday, 26'th Feb 2025
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
07:00am, Wednesday, 19'th Feb 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
11:26am, Monday, 17'th Feb 2025
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
10:55am, Monday, 13'th Jan 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the po
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Friday, 10'th Jan 2025
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
